sales@contrivedatuminsights.com
CDI - Contrive Datum Insights
IT, Software & Telecom

Healthcare Equipment Leasing MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Lease TypeBy Equipment ConditionBy Lease Duration

Full title & scope — all 5 axes with their segments

Healthcare Equipment Leasing Market Size, Share & Industry Analysis, By Type (Surgical and Therapy Leasing Equipment, Digital and Electronic Equipment, Storage and Transport Leasing Equipment, Personal and Homecare Leasing Equipment, DME), By Application (Hospitals, Diagnostic Centers, Others), By Lease Type (Operating Lease, Finance Lease, Rental), By Equipment Condition (New Equipment, Refurbished/Pre-owned Equipment), By Lease Duration (Short-term Lease, Long-term Lease), and Regional Forecast, 2026-2034

Last Updated: Sep 21, 2026Report ID: CDI-57716
Methodology

How the estimates were built: data sources, modelling approach and validation steps.

Research approach

A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.

Market size estimation, this report

The estimate is built upward from the installed base of leased medical equipment across hospitals, diagnostic centers and homecare settings, multiplied by realized lease rates for each equipment category: surgical and therapy systems, imaging and monitoring equipment, and mobility or durable medical equipment units. Utilization rates and replacement-cycle assumptions convert unit counts into annual leased-equipment revenue. This build is checked against disclosed equipment-finance and leasing revenue from named lessors and OEM captive-finance arms; where the unit-and-rate build diverges from what a company's own disclosure implies for its regional book, the unit count or lease-rate assumption feeding the build is corrected, not averaged against the disclosed figure.

The four stages

The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.

1
Scope and segmentation
2
Bottom-up sizing
3
Reconciliation
4
Forecast

What the build rests on, and what checks it

The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.

The bottom-up build rests on
  • Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
  • Realised pricing by tier and channel, rather than one blended average applied across the whole market
  • Take-up and frequency: how much of the addressable base buys, and how often it repeats
The build is checked against
  • Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
  • Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
  • Trade and customs flows, where the product crosses borders in a separately recorded form
Bottom-up sequence
1
Size the base
2
Apply take-up
3
Apply frequency
4
Apply realised price
Reconciliation sequence
1
Gather disclosed revenue
2
Strip out-of-scope lines
3
Compare against the build
4
Correct the assumption

Data sources

Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.

Primary — who is interviewed
  • Commercial and product leadership at the companies that supply the market
  • Procurement and specification leads at the organisations that buy it
  • Distributors, integrators and channel partners, where the market is served indirectly
  • Regulatory and standards specialists, where approval governs what can be sold at all
Secondary — what is read
  • Company filings, annual reports and investor disclosure
  • Government statistics, customs records and regulatory registers
  • Trade association output and standards-body publications
  • Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research design, this report

Interviews target equipment-leasing program managers, hospital procurement and biomedical engineering leads, OEM captive-finance representatives and independent lessors' regional sales managers, since these roles set lease terms, renewal cycles and utilization thresholds. Sampling weights North America and Western Europe, where leasing penetration and disclosure are deepest, while adding targeted conversations in China, India and the Gulf states to capture procurement patterns in markets where leasing is newer and less documented. Regulatory affairs contacts at hospital networks are also included to confirm how reimbursement and capital-budget cycles shape lease-versus-purchase decisions.

Secondary sources, this report

Desk research draws on hospital capital-expenditure disclosures in public health-system financial statements, equipment-finance segment reporting from named OEM captive-finance units, U.S. HCPCS and CMS durable-medical-equipment fee schedules that shape lease-versus-purchase economics, FDA device-registration and 510(k) listings confirming which equipment categories are in active clinical use, and customs trade data under HS heading 9018 and 9019 for cross-border equipment shipments feeding leasing pools. National health-expenditure statistics from Eurostat and the OECD supplement regional demand estimates where company-level disclosure is thin.

Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.

Forecasting

The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.

Forecast approach, this report

The forecast rests on continued hospital preference for capital-light equipment access, the pace at which digital and electronic equipment categories are refreshed against shortening technology cycles, and the rate at which home-based and outpatient care shifts leased-equipment demand outside acute settings. Reimbursement policy is treated as a pricing input rather than a fixed constant, since coverage changes alter what providers can recover on leased diagnostic and monitoring equipment. The forecast normalizes for the unusually high leasing demand recorded during the pandemic period so that later years reflect underlying structural adoption instead of a temporary surge.

Triangulation and validation

No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.

Validation, this report

Historical output was back-tested against recorded growth in hospital capital-expenditure and equipment-finance disclosures for 2020 through 2024, confirming the bottom-up build reproduces observed trends before it is extended forward. Segment-level shifts, particularly the move toward digital and electronic equipment and away from storage and transport categories, were reviewed against procurement specialists' own account of purchasing patterns. Sensitivities were run on lease-rate assumptions and on the pace of the home-care shift, since these two inputs move the forecast total more than any other single assumption.

Confidence and limitations

Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.

Confidence framing, this report

Confidence is firmest for hospital-based surgical and therapy leasing in North America and Europe, where equipment-finance disclosure is regular and lease-rate benchmarks are observable. It is thinner for homecare and diagnostic-center leasing in Asia Pacific, Latin America and the Middle East and Africa, where reporting is less consistent and leasing penetration is still forming. A shift in reimbursement policy for leased diagnostic equipment, or a faster-than-expected move of procedures out of hospitals, are the structural risks most likely to force a revision to this estimate.

Scope

Questions This Report Answers

6 questions
01

What is the market size and growth rate, globally and by region?

02

How is the market segmented, and which segments lead?

03

Which regions and countries are covered, and how do they compare?

04

What are the key drivers, restraints, opportunities and challenges?

05

Who are the leading companies operating in this market?

06

What trends are expected to shape the market through the forecast period?

Questions

Frequently Asked Questions

01What is the Healthcare Equipment Leasing Market projected to reach?

USD 103.92 Billion by 2034, CAGR 6.6%

02What years does this report cover?

Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.

03Which regions are covered?

North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

04Which region accounted for the largest market share?

North America leads with 34.21% of global revenue through 2034.

05Which segment leads the market?

Surgical and Therapy Leasing Equipment is the largest line by type, at 32.21% of revenue in 2025.

06Who are the key companies profiled?

De Lage Landen International, GE Capital, National Technology Leasing, Oak Leasing, Rotech Healthcare, Siemens Financial Services.. Full profiles are part of the paid report.

07Can the segmentation be customized?

Yes. Custom data cuts by geography, segment, or competitor set are available on request.

425+
Dedicated research analysts
1,200+
Reports published
Why CDI

Why choose CDI

Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available

Need this report shaped around your question?

The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.

Most licences include 3060 hours of customization at no extra cost. See what each licence includes

Request customization

Additional Companies

Add competitors, suppliers or the peer set you benchmark against to the companies already covered.

Deeper Competitive View

Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.

Extra Segment Splits

Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.

Application Focus

Narrow the analysis to the specific use cases and end users your team actually sells into.

Different Time Frame

Move the base year, or widen the historical and forecast windows the study is built on.

Country-Level Detail

Go below region level into the individual countries that matter to you, rather than the standard geography split.